

How Avastin Reshapes OC Treatment ?

A regrettable case.....







就如同法庭上聽到審判結果一樣

每次回診聽到疾病又復發,

Ovarian Cancer




70% of women relapse within 3 years of frontline treatment²


30%–40% 5-year survival rate¹

1. Reid BM et al. Cancer Biol Med. 2017;14(1):9-32. 2. Ledermann JA et al. Ann Oncol. 2013;24(Suppl 6):vi24-vi32.


The Typical Course of Advanced Ovarian Cancer¹⁻⁵

Ledermann JA et al. *Ann Oncol.* 2013;24(Suppl 6):vi24-vi32.
Giornelli GH. *Springerplus*. 2016;5(1):1197.
Pignata S et al. *Ann Oncol.* 2017;28(suppl_8):viii51-viii56.
du Bois A et al. *Cancer*. 2009;115(6):1234-1244.
Wilson MK et al. *Ann Oncol.* 2017;28(4):727-732.






^a mPFS values measured from beginning of chemotherapy (ie, day of randomization) to the first disease progression and, thereafter, from one progression to the subsequent one or to death. L, line; mPFS, median progression-free survival; PFS, progression-free survival. Hanker LC, et al. Ann Oncol. 2012;23(10):2605-12.





^a mPFS values measured from beginning of chemotherapy (ie, day of randomization) to the first disease progression and, thereafter, from one progression to the subsequent one or to death. L, line; mPFS, median progression-free survival; PFS, progression-free survival. Hanker LC, et al. Ann Oncol. 2012;23(10):2605-12.




^a mPFS values measured from beginning of chemotherapy (ie, day of randomization) to the first disease progression and, thereafter, from one progression to the subsequent one or to death. L, line; mPFS, median progression-free survival; PFS, progression-free survival. Hanker LC, et al. Ann Oncol. 2012;23(10):2605-12.










OCEANS: A Randomized, Double-Blind, Phase III Trial of Avastin + Chemotherapy in Platinum-Sensitive Ovarian Cancer (Dec 6, 2016)


OCEANS: A Randomized, Double-Blind, Phase III Trial of Avastin +Chemotherapy in Platinum-Sensitive Ovarian Cancer (Dec 6, 2016)



1. Avastin[®] (bevacizumab) [prescribing information]. South San Francisco, CA: Genentech, Inc.; 2017.

2. Aghajanian C, Blank S, Goff B, et al. J Clin Oncol. 2012;30(17):2039-2045.

OCEANS: A Randomized, Double-Blind, Phase III Trial of Avastin +Chemotherapy in Platinum-Sensitive Ovarian Cancer (Dec 6, 2016)




1. Avastin[®] (bevacizumab) [prescribing information]. South San Francisco, CA: Genentech, Inc.; 2017.

2. Aghajanian C, Blank S, Goff B, et al. J Clin Oncol. 2012;30(17):2039-2045.

GOG 213: A Randomized, Open-label, Phase III Trial of Avastin + Chemotherapy in Platinum-Sensitive Ovarian Cancer (Dec 6, 2016)


GOG 213: A Randomized, Open-label, Phase III Trial of Avastin + Chemotherapy in Platinum-Sensitive Ovarian Cancer (Dec 6, 2016)



*The GOG 213 Study also evaluated the effect of secondary cytoreduction. AUC=area under the curve; GOG=Gynecologic Oncology Group; ORR=objective response rate; OS=overall survival; PFS=progression-free survival; PS=performance status; ULN=upper limit of normal.

1. Avastin® (bevacizumab) [prescribing information]. South San Francisco, CA: Genentech, Inc.; 2016. 2. Data on File. Genentech, Inc.

GOG 213: A Randomized, Open-label, Phase III Trial of Avastin + Chemotherapy in Platinum-Sensitive Ovarian Cancer (Dec 6, 2016)




*The GOG 213 Study also evaluated the effect of secondary cytoreduction. AUC=area under the curve; GOG=Gynecologic Oncology Group; ORR=objective response rate; OS=overall survival; PFS=progression-free survival; PS=performance status; ULN=upper limit of normal.

1. Avastin® (bevacizumab) [prescribing information]. South San Francisco, CA: Genentech, Inc.; 2016. 2. Data on File. Genentech, Inc.


AURELIA: A Randomized, Open-label Phase III Trial of Bevacizumab + Chemotherapy in Platinum-Resistant Ovarian Cancer (Nov 14, 2014)

AURELIA: A Randomized, Open-label Phase III Trial of Bevacizumab + Chemotherapy in Platinum-Resistant Ovarian Cancer (Nov 14, 2014)

Aurelia: PFS/OS








GOG 218: Incorporation of bevacizumab in the primary treatment of ovarian cancer

GOG-0218: Investigator-assessed PFS



Progression-Free Survival(months)

1. Burger RA, et al. NEJM 2011

^{2.} Label of TFDA


GOG-0218: Investigator-assessed PFS

1.0 - abel 0.8 - CPP (N=625) CPB15 (N=625) CPB15+ (N=623) + Censored										
Regimen		Arm1 (CPP)			Arm2 (CPB15)		Arm	Arm3 (срв15+)		
Protocol-defined median PFS (months)		12.0	12.0			12.8 HR=0.83 (0.70-0.98) P=0.0204		18.2 HR=0.62 (0.52-0.75) P<0.0001		
CPP CPB15 CPB15+	625	391 409 419	152 173 193	52 65 75	21 22 27	11 10 9	6 5 5	1		
	0	6	12	18	24	30	36	42	48	

Progression-Free Survival(months)

1. Burger RA, et al. NEJM 201[°]

2. Label of TFDA



Maintenance Treatment +/- bevacizumab or +/- PARPi and Follow-up

First-Line Treatment Stage III, IV

First Response*

Surgery (primary or IDS) + primary or adjuvant chemotherapy

後續還能用Avastin嗎

Platinum-Sensitive Platinum is an option; Progression > 6 mont

completion of platinum-based chemotherapy


Platinum-Resistant

Platinum is not an option; Progression <6 months after completion of platinum-based chemotherapy

*Around 5% of patients are primary treatment-refractory, meaning disease progressed during therapy or within 4 weeks after the last dose.

Subgroup analysis of OS in GOG - 0213

Patients enrolled in the study have been re-treated with Avastin as part of primary therapy and/or maintenance therapy (n=34 in the CT alone arm; n=35 in the Avastin plus CT arm).




Prior Bevacizumab ORR%

Carboplatin + paclitaxel



Carboplatin + paclitaxel + bevacizumab



Prior Bevacizumab ORR%

Carboplatin + paclitaxel



Carboplatin + paclitaxel + bevacizumab

• GOG-0213: over 80% of ORR in patients re-treated with bevacizumab in 2nd line treatment

A delightful case.....

66 y/o female, ovarian cancer , stage IVB , umbilicus metastasis

200



carboplatin + Paclitaxel

chemotherapy with 6 months later First Recurrence

Combined Avastin with chemotherapy for 6 cycles,

complete remission then maintenance with Avastin w/o chemotherapy for 1.5 year



66 y/o female, ovarian cancer , stage IVB , umbilicus metastasis

chemotherapy with carboplatin + Paclitaxel 6 months later First Recurrence

Combined Avastin with chemotherapy for 6 cycles,

w/o chemotherapy for **1.5** year

complete remission then maintenance with Avastin

F/U: No Disease Progression



1. 前期就可用

1. 前期就可用

2. 復發也可用

1. 前期就可用

2. 復發也可用



Reshapes OC Treatment!